Outlook 2024: CAR-T Cell Therapy
I would like to wish all my readers a happy, joyful and above all healthy new year 2024. At the beginning of a year, one is sometimes asked where one sees interesting potentials in terms
Continue reading
Tag: B-cells
B-cell depleters lower immunoglobulin levels
What exactly are immunoglobulins, why do we need them and why are they reduced in some people by the so-called B-cell depleters Ocrelizumab and Ofatumumab? Do you always have to take action with low immunoglobulin
Continue reading
ECTRIMS 2021 (2): Vaccination in Multiple Sclerosis – Joint Consensus from ECTRIMS and EAN
The pandemic and the discussions about vaccinating MS patients against COVID19 have shown the need for a common European approach regarding recommendations for vaccinating MS sufferers. Therefore, after the last ECTRIMS Congress in 2020, representatives
Continue reading
ECTRIMS 2021 (1): Vaccination against SARS-CoV2
This year, the ECTRIMS Congress was again held virtually due to the pandemic. While this was a pity, as large international congresses thrive on the personal exchange between doctors and scientists, there was still plenty
Continue reading
COVID 19 Vaccination and Immunotherapy – Focus on Ocrelizumab
How does immunotherapy for MS and the COVID-19 vaccination relate? This question is currently being asked frequently by my patients. As already mentioned in some blog posts about vaccination and MS, the COVID-19 vaccination poses
Continue reading
Approval of Ocrelizumab
As of this week, Ocrevus® (Ocrelizumab) is available for prescription and in pharmacies for the treatment of relapsing-remitting (RMS) and primary progressive Multiple Sclerosis (PPMS). Given the good clinical efficacy data and acceptable safety profile,
Continue reading
Cladribin – a new option for relapsing MS
On August 25, 2017, the European Medicines Commission EMA approved the active ingredient Cladribin under the trade name MAVENCLAD® for the treatment of relapsing multiple sclerosis (MS) in patients with high disease activity.
Continue reading
